The future of multiple sclerosis treatments

被引：8

作者：

Coclitu, Catalina ^{[1
]}

Constantinescu, Cris S. ^{[2
]}

Tanasescu, Radu ^{[2
,3
]}

机构：

[1] Univ Hosp, Dept Neurol, Bucharest, Romania

[2] Univ Nottingham, Acad Clin Neurol, Div Clin Neurosci, Nottingham, England

[3] Univ Med & Pharm Carol Davila, Colentina Hosp, Dept Neurol Neurosurg & Psychiat, Bucharest, Romania

来源：

EXPERT REVIEW OF NEUROTHERAPEUTICS | 2016年 / 16卷 / 12期

关键词：

Multiple sclerosis; immunomodulation; monoclonal antibodies; remyelination; repurposing; STEM-CELL TRANSPLANTATION; PLACEBO-CONTROLLED TRIAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; DISEASE-MODIFYING THERAPIES; HIGH-YIELD PROCESS; HIGHLY-ACTIVE MS; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; CUTANEOUS ADVERSE EVENTS;

D O I：

10.1080/14737175.2016.1243056

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Introduction: There are not many conditions in which the last few decades have brought such a major change in the landscape of treatments as is the case of multiple sclerosis (MS). A number of disease modifying treatments (DMTs) are presently available for the treatment of the inflammatory phase of this disabling disease; however, the need for treating neurodegeneration and halting the progression of disability is still unmet.Areas covered: In this paper we review the available information on existing and emerging DMTs and we discuss their place within the context of different treatment strategies in MS,Expert commentary: The future of MS treatments should include the development of new treatment strategies tackling disease progression, together with a better understanding of the side-effects and the best sequential strategy of implementation of available and emerging drugs.

引用

页码：1341 / 1356

页数：16

共 211 条

[91] Inclusion of brain volume loss in a revised measure of "no evidence of disease activity' (NEDA-4) in relapsing-remitting multiple sclerosis [J].

Kappos, Ludwig ;

De Stefano, Nicola ;

Freedman, Mark S. ;

Cree, Bruce A. C. ;

Radue, Ernst-Wilhelm ;

Sprenger, Till ;

Sormani, Maria Pia ;

Smith, Terence ;

Haring, Dieter A. ;

Meier, Daniela Piani ;

Tomic, Davorka .

MULTIPLE SCLEROSIS JOURNAL, 2016, 22 (10) :1297-1305

[92] The 11-year long-term follow-up study from the randomized BENEFIT CIS trial [J].

Kappos, Ludwig ;

Edan, Gilles ;

Freedman, Mark S. ;

Montalban, Xavier ;

Hartung, Hans-Peter ;

Hemmer, Bernhard ;

Fox, Edward J. ;

Barkhof, Frederik ;

Schippling, Sven ;

Schulze, Andrea ;

Pleimes, Dirk ;

Pohl, Christoph ;

Sandbrink, Rupert ;

Suarez, Gustavo ;

Wicklein, Eva-Maria .

NEUROLOGY, 2016, 87 (10) :978-987

[93] Long-term effects of fingolimod in multiple sclerosis The randomized FREEDOMS extension trial [J].

Kappos, Ludwig ;

O'Connor, Paul ;

Radue, Ernst-Wilhelm ;

Polman, Chris ;

Hohlfeld, Reinhard ;

Selmaj, Krzysztof ;

Ritter, Shannon ;

Schlosshauer, Rolf ;

von Rosenstiel, Philipp ;

Zhang-Auberson, Lixin ;

Francis, Gordon .

NEUROLOGY, 2015, 84 (15) :1582-1591

[94] Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial [J].

Kappos, Ludwig ;

Li, David ;

Calabresi, Peter A. ;

O'Connor, Paul ;

Bar-Or, Amit ;

Barkhof, Frederik ;

Yin, Ming ;

Leppert, David ;

Glanzman, Robert ;

Tinbergen, Jeroen ;

Hauser, Stephen L. .

LANCET, 2011, 378 (9805) :1779-1787

[95] A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis [J].

Kappos, Ludwig ;

Radue, Ernst-Wilhelm ;

O'Connor, Paul ;

Polman, Chris ;

Hohlfeld, Reinhard ;

Calabresi, Peter ;

Selmaj, Krzysztof ;

Agoropoulou, Catherine ;

Leyk, Malgorzata ;

Zhang-Auberson, Lixin ;

Burtin, Pascale .

NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (05) :387-401

[96] Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial [J].

Kappos, Ludwig ;

Freedman, Mark S. ;

Polman, Chris H. ;

Edan, Gilles ;

Hartung, Hans-Peter ;

Miller, David H. ;

Montalban, Xavier ;

Barkhof, Frederik ;

Radue, Ernst-Wilhelm ;

Metzig, Carola ;

Bauer, Lars ;

Lanius, Vivian ;

Sandbrink, Rupert ;

Pohl, Christoph .

LANCET NEUROLOGY, 2009, 8 (11) :987-997

[97]

Karussis D, 1999, MULT SCLER, V5, P17, DOI 10.1177/135245859900500104

[98]

Karussis D, 2013, EXPERT REV NEUROTHER, V13, P567, DOI [10.1586/ern.13.36, 10.1586/ERN.13.36]

[99] T Cell Vaccination Benefits Relapsing Progressive Multiple Sclerosis Patients: A Randomized, Double-Blind Clinical Trial [J].

Karussis, Dimitrios ;

Shor, Hagai ;

Yachnin, Julia ;

Lanxner, Naama ;

Amiel, Merav ;

Baruch, Keren ;

Keren-Zur, Yael ;

Haviv, Ofra ;

Filippi, Massimo ;

Petrou, Panayiota ;

Hajag, Shalom ;

Vourka-Karussis, Urania ;

Vaknin-Dembinsky, Adi ;

Khoury, Salim ;

Abramsky, Oded ;

Atlan, Henri ;

Cohen, Irun R. ;

Abulafia-Lapid, Rivka .

PLOS ONE, 2012, 7 (12)

[100]

Karussis D, 2010, ARCH NEUROL-CHICAGO, V67, P1187, DOI 10.1001/archneurol.2010.248

← 5 6 7 8 9 10 11 12 13 14 →